Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 1,853 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Mental Illness Clear all
Active, not recruiting Not applicable Interventional

Accelerated TMS for MDD

NCT07147218
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
TMS
Device
Lead sponsor
Neuronetics
Other
Eligibility
15 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
New York, New York • Charlotte, North Carolina • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 16, 2026, 9:33 AM EDT
Recruiting Not applicable Interventional

Exercise-based Program for Rehabilitation of Veterans With Severe Mental Illness

NCT05157620
View directory record Official record
Conditions
Schizophrenia, Schizoaffective, Bipolar Disorder 1
Interventions
Yoga-based Exercise (YE), Wellness Lifestyle Program (WLP)
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 16, 2026, 9:33 AM EDT
Recruiting Phase 4 Interventional

Biomarker-Guided Antidepressant Selection

NCT07680140
View directory record Official record
Conditions
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD), rTMS, Ketamine, fMRI
Interventions
TMS, Ketamine
Device · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 16, 2026, 9:33 AM EDT
Completed Not applicable Interventional Results available

Sleep-Disordered Breathing and PAP in Perinatal Depression

NCT02507297
View directory record Official record
Conditions
Sleep-disordered Breathing, Major Depressive Disorder
Interventions
Positive Airway Pressure (PAP)
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 1, 2023 · Synced Oct 16, 2026, 9:33 AM EDT
Withdrawn Phase 4 Interventional

Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease

NCT00711204
View directory record Official record
Conditions
Severe Alzheimer's Disease
Interventions
Donepezil Hydrochloride (Aricept)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Oct 16, 2026, 9:33 AM EDT
Completed Phase 4 Interventional

A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD)

NCT00321152
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
6(S)-5-MTHF (a Medical Food)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
11
States / cities
San Diego, California • Chicago, Illinois • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2010 · Synced Oct 16, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

NCT01157078
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2014 · Synced Oct 16, 2026, 9:33 AM EDT
Completed Phase 4 Interventional

An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder

NCT00330655
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
memantine
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
16 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2007 · Synced Oct 16, 2026, 9:33 AM EDT
Terminated Not applicable Interventional Results available

Stimulant Enhancement of Well-Being Therapy for Depression

NCT01478113
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Amphetamine/dextroamphetamine, Placebo, Well-being therapy
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 16, 2026, 9:33 AM EDT
Completed Not applicable Interventional

e-Mindfulness for Depression in Older Adults

NCT03922217
View directory record Official record
Conditions
Depression, Mental Health Disorder
Interventions
Mindful My Way
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 24, 2024 · Synced Oct 16, 2026, 9:33 AM EDT
Completed Phase 1 Interventional Results available

A Study of LY2216684 in Major Depressive Disorder in Patients Taking Selective Serotonin Reuptake Inhibitors

NCT01263223
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
LY2216684, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
St Louis, Missouri • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 16, 2026, 9:33 AM EDT
Completed Phase 1 Interventional Results available

Antidepressant Effects of NR2B in Major Depression

NCT00472576
View directory record Official record
Conditions
Major Depression
Interventions
MK-0657, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2012 · Synced Oct 16, 2026, 9:33 AM EDT
Completed Phase 2 Interventional

A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression

NCT00624858
View directory record Official record
Conditions
Depression
Interventions
naltrexone SR 32 mg/ bupropion SR 360 mg daily
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Oct 16, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Results available

A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)

NCT03537014
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Therapy, midomafetamine HCl, Placebo
Behavioral · Drug
Lead sponsor
Resilient Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
North Hollywood, California • San Francisco, California • Boulder, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 16, 2026, 9:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HIV Prevention for Youth With Severe Mental Illness

NCT00496691
View directory record Official record
Conditions
HIV Infections
Interventions
Family-based HIV prevention program
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
13 Years to 18 Years
Enrollment
718 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 16, 2026, 9:33 AM EDT
Completed Not applicable Interventional

Cognitive Deficits in Major Depressive Disorder and Bipolar Disorder, Depressed Type: Prevalence and Improvement With Treatment of Depressive Symptoms

NCT00844974
View directory record Official record
Conditions
Major Depression, Bipolar Disorder
Interventions
Prevalence
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Oct 16, 2026, 9:33 AM EDT
Terminated Phase 1 Interventional

A Study to Assess Adverse Events of Fosigotifator (ABBV-CLS-7262) in Adults With Major Depressive Disorder

NCT06618118
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Fosigotifator, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
20 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Sherman Oaks, California • Orlando, Florida • Decatur, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 16, 2026, 9:33 AM EDT
Recruiting Phase 2 Interventional

5-HTP and Creatine for Depression R33 Phase

NCT05895747
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Low Dose 5-hydroxytryptophan, High Dose 5-hydroxytryptophan, Low Dose Creatine Monohydrate, High Dose Creatine Monohydrate, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 16, 2026, 9:33 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Near Infrared Spectroscopy (NIRS) for Assessment of Depression

NCT04061148
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NIRSIT
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 16, 2026, 9:33 AM EDT
Completed Not applicable Interventional

Clinical Trials of Three Non-Drug Treatments for Winter Depression (SAD)

NCT00006517
View directory record Official record
Conditions
Seasonal Affective Disorder, Mood Disorders, Depression
Interventions
bright light box, dawn simulator, high-output negative ion generator, low-output negative ion generator, dawn light pulse
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 16, 2026, 9:33 AM EDT
Completed Not applicable Interventional

Cognitive Behavioral Group Therapy for the Management of Menopause Symptoms in Mood Disorders

NCT02860910
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder, Menopause
Interventions
Cognitive Behavioral Group Therapy
Behavioral
Lead sponsor
Danette Conklin, PhD
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Oct 16, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation

NCT00167310
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Coronary Artery Disease
Interventions
Eicosapentaenoic acid (omega-3 fatty acid), Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 16, 2026, 9:33 AM EDT
Completed Not applicable Interventional Results available

Investigating the Effectiveness of Telepsychiatry for Treating Major Depression in a Chinese American Nursing Home

NCT00505518
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Psychotropic medication (at discretion of psychiatrist), Collaborative psychiatric and primary medical care
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 16, 2026, 9:33 AM EDT
Not listed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

NCT04480333
View directory record Official record
Conditions
Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response
Interventions
Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Placebo 0.20 mg + 2.00 mg/kg
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 16, 2026, 9:33 AM EDT